Table of Contents Table of Contents
Previous Page  3 / 32 Next Page
Information
Show Menu
Previous Page 3 / 32 Next Page
Page Background

TRATAMIENTO SISTÉMICO DEL CCRm.

Primera línea

Estudio

N

RG (%)

SLP (meses)

SG (meses)

Sunitinib

vs.

IFNα

750

47

vs.

12

11.0

vs.

5.0

p<0.001

26.4

vs.

21.8

p=0.051

AVOREN

Bevacizumab + IFNα

vs.

IFNα + placebo

649

31

vs.

12

10.4

vs.

5.5

p<0.0001

23.3

vs.

21.3

p=0.1291

CALGB 90206

Bevacizumab + IFNα

vs.

IFNα

732

25.5

vs.

13.1

8.4

vs.

4.9

p<0.0001

18.3

vs.

17.4

p=0.069

VEG105192

Pazopanib

vs.

placebo

233

32

vs.

3

11.1

vs.

2.8

p<0.00001

NA

COMPARZ

Pazopanib

vs.

sunitinib

1100

31

vs.

25

10.5

vs.

10.2

NS

28.4

vs.

29.3

NS

ARCSS

Temsirolimus

vs.

IFNα

626

8.6

vs.

4.6

3.8 vs. 1.9

p<0.001

10.9

vs.

7.3

p=0.008

Motzer RJ, et al. N Engl J Med 2007; 356(2):115.

Escudier B, et al. Lancet 2007;370:2103.

Rini BI, et al. J Clin Oncol 2008;26(33):5422.

Sternberg CN, et al. J Clin Oncol 2010;28(6):1061.

Motzer RJ, et al. N Engl J Med 2013;369(8):722.

Hudes G, et al. N Engl J Med 2007;356:115.